Cargando…
Inhibition of PGE(2)/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress
The platinum-based chemotherapeutic agent, oxaliplatin, is used to treat advanced colorectal cancer (CRC). Unfortunately, nearly all patients acquire resistance to oxaliplatin after long-term use, limiting its therapeutic efficacy. Since COX-2 and PGE(2) signaling can impact colon cancer cell prolif...
Autores principales: | Huang, Huakang, Aladelokun, Oladimeji, Ideta, Takayasu, Giardina, Charles, Ellis, Lee M., Rosenberg, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427013/ https://www.ncbi.nlm.nih.gov/pubmed/30894570 http://dx.doi.org/10.1038/s41598-019-40848-4 |
Ejemplares similares
-
Fatty acid metabolism and colon cancer protection by dietary methyl donor restriction
por: Aladelokun, Oladimeji, et al.
Publicado: (2021) -
Changing prostaglandin E2 (PGE(2)) signaling during lesional progression and exacerbation of endometriosis by inhibition of PGE(2) receptor EP2 and EP4
por: Huang, Qingqing, et al.
Publicado: (2021) -
Effect of selective inhibition or activation of PGE2 EP1 receptor on glomerulosclerosis
por: Chen, Xu, et al.
Publicado: (2020) -
COX-2-PGE(2)-EPs in gynecological cancers
por: Ye, Yao, et al.
Publicado: (2020) -
Role of the PGE(2) receptor subtypes EP1, EP2, and EP3 in repetitive traumatic brain injury
por: Catlin, James, et al.
Publicado: (2019)